SCHEMBL4575338

SCHEMBL4575338

CCc1cnc(N(Cc2ccc(OC(F)(F)F)cc2)CC(C)(C)c2ccc(OC(C)(C)C(=O)O)cc2)nc1

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.42
PPARD Q03181 11/20 0.42
PPARG P37231 8/20 0.42
TRPM8 Q7Z2W7 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4574756 0.95 PPARA (0.48) PPARAPPARDPPARG
SCHEMBL4575895 0.91 PPARA (0.44) PPARAPPARDPPARG
SCHEMBL4575080 0.89 PPARA (0.47) PPARAPPARDPPARGTRPM8
SCHEMBL4576109 0.89 SMN1; SMN2 (0.42) PPARAPPARDTRPM8
SCHEMBL4575134 0.88 PPARA (0.41) PPARAPPARDPPARGTRPM8
SCHEMBL4575175 0.88 TRPM8 (0.39) TRPM8
SCHEMBL4575828 0.86 PPARA (0.47) PPARAPPARDPPARG
SCHEMBL4575223 0.85 PPARA (0.42) PPARAPPARDPPARGTRPM8
SCHEMBL4575105 0.83 PPARA (0.52) PPARAPPARDPPARG
SCHEMBL4576118 0.83 PPARA (0.41) PPARAPPARDPPARGTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US claimed
US-20050137212-A1 Hppars activators SMITHKLINE BEECHAM CORPORATION 2005-06-23 US claimed
EP-1480957-A1 HPPARS ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-01 EP claimed
WO-2003074495-A1 HPPARS ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-12 WO claimed
US-20230127775-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS ULTRAGENYX PHARMACEUTICAL INC. 2023-04-27 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-20050137212-A1 Hppars activators SMITHKLINE BEECHAM CORPORATION 2005-06-23 US disclosed
EP-1480957-A1 HPPARS ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-01 EP disclosed
WO-2003074495-A1 HPPARS ACTIVATORS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127775-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS GAA, LIPA, TTR PPARA 2117/4885PPARD 3779/4885PPARG 2661/4885
US-20050137212-A1 Hppars activators PPARG, PPARA, PPARD PPARA 2/4885PPARD 3/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.